Sean P. Nolan - 12 Jan 2026 Form 4 Insider Report for Taysha Gene Therapies, Inc. (TSHA)

Role: Chief Executive Officer, Director
Signature: /s/ Kamran Alam, Attorney-in-Fact
Issuer symbol: TSHA
Transactions as of: 12 Jan 2026
Net transactions value: $0
Form type: 4
Filing time: 14 Jan 2026, 16:45:09 UTC
Previous filing: 17 Feb 2026
Next filing: 27 Jan 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Nolan Sean P.	Chief Executive Officer, Director	C/O TAYSHA GENE THERAPIES, INC., 3000 PEGASUS PARK DRIVE, SUITE 1430, DALLAS	/s/ Kamran Alam, Attorney-in-Fact	14 Jan 2026	0001569926

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TSHA	Common Stock	Award	$0	+1,008,000	+48%	$0.000000	3,086,358	12 Jan 2026	Direct	F1
holding	TSHA	Common Stock						1,535,545	12 Jan 2026	See footnote	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TSHA	Employee Stock Option (right to buy)	Award	$0	+648,000		$0.000000	648,000	12 Jan 2026	Common Stock	648,000	$4.86	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents a restricted stock unit ("RSU") award. The RSUs will vest in four equal annual installments beginning on January 12, 2027, subject to the Reporting Person's continuous service through each applicable vesting date.
F2	The securities are held by Nolan Capital, LLC (the "LLC"). The Reporting Person is the President of the LLC and has shared voting and investment power with respect to the shares held by the LLC.
F3	25% of the total number of shares underlying the option shall vest and become exercisable on January 12, 2027 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.